Seaport Therapeutics and Hemab Therapeutics continued the IPO resurgence with upsized offerings. Seaport joined Nasdaq on May 1 with gross proceeds of $254.9 million, while Hemab priced a $301.5 million upsized IPO, reflecting strong investor appetite for early commercial trajectories and late-stage readiness in select therapeutic areas. In parallel, Hypervision Surgical secured a £17 million (US$23 million) Series A to fund its surgical hyperspectral imaging platform, aiming to provide surgeons real-time tissue physiology insights during procedures using spectral sensing plus cloud-enabled AI analytics. Together, the deals illustrate continued capital access for biotechs tied to near-term clinical or platform differentiation, even as broader market conditions remain uneven across diagnostics, drug development, and medtech.